Loading clinical trials...
Loading clinical trials...
A Phase Ib Study of 9-ING-41 (Elraglusib), a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Modified FOLFIRINOX as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Conditions
Interventions
Retifanlimab
Chemotherapy
+1 more
Locations
1
United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Start Date
September 22, 2025
Primary Completion Date
September 30, 2027
Completion Date
December 31, 2028
Last Updated
September 29, 2025
NCT07409272
NCT04605913
NCT06998940
NCT06778863
NCT06381154
NCT05825066
Lead Sponsor
Anwaar Saeed
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions